By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chinese molecular diagnostics firm Amoy Diagnostics today announced the Chinese State Food and Drug Administration has approved its KRAS mutation detection kit.

The Xiamen-based firm can now market its KRAS test for clinical use in China. In a statement, AmoyDx said the KRAS kit is the first molecular diagnostic assay to receive approval in China for use in personalized clinical testing in oncology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.